Full Press Release Details
garetosmab biologics license application accepted for fda priority review for the treatment of fibrodysplasia ossificans progressiva fop.
REGN
garetosmab biologics license application accepted for fda priority review for the treatment of fibrodysplasia ossificans progressiva fop
Key Takeaway: garetosmab biologics license application accepted for fda priority review for the treatment of fibrodysplasia ossificans progressiva fop